164. Prospective Multi Centered Study on the Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis Patients

• Published in: Multiple sclerosis and related disorders 2024-12, Vol.92, p.106125, Article 106125
• Main Authors: Al-Mahdawi, Akram M., Hatem, Anmar Oday, Aayd, Ismael Raje
• Format: Article
• Language: English
• ISSN: 2211-0348
• DOI: 10.1016/j.msard.2024.106125

In the context of evolving treatments for multiple sclerosis (MS), the introduction of ocrelizumab represents a significant advancement. Its effectiveness and safety warrant thorough investigation contributing valuable insights to MS management strategies. This study aims to evaluate the effectiveness and safety of ocrelizumab in patients with primary progressive MS (PPMS). The Cohort included 151 patients 77(51%) males and 74(49%) females with a mean age 41±10; the majority of participants received two doses. The average EDSS score of patients was significantly increased from 4.851 to 5.026 with 34 (22.5%) had confirmed disability progression. There was significant reduction in the progression index from 1.030 to 0.909 between two visits. Brain MRI showed a substantial reduction in the number of T2 lesions from 8 to 7 with stable spinal MRI lesions. Ocrelizumab was well tolerated with most common adverse events were infusion related out of which 99% were classified as mild. reactions. The results showed that Ocrelizumab seems successful in slowing down the advancement of the illness and reducing the development of MRI lesions in patients with MS.